000153121 001__ 153121
000153121 005__ 20240229123040.0
000153121 0247_ $$2doi$$a10.1186/s12902-019-0485-x
000153121 0247_ $$2pmid$$apmid:31931801
000153121 0247_ $$2altmetric$$aaltmetric:74134689
000153121 037__ $$aDKFZ-2020-00203
000153121 041__ $$aeng
000153121 082__ $$a610
000153121 1001_ $$aKartschmit, Nadja$$b0
000153121 245__ $$aWalkability and its association with prevalent and incident diabetes among adults in different regions of Germany: results of pooled data from five German cohorts.
000153121 260__ $$a[S.l.]$$bBioMed Central$$c2020
000153121 3367_ $$2DRIVER$$aarticle
000153121 3367_ $$2DataCite$$aOutput Types/Journal article
000153121 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1579098344_8526
000153121 3367_ $$2BibTeX$$aARTICLE
000153121 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153121 3367_ $$00$$2EndNote$$aJournal Article
000153121 520__ $$aHighly walkable neighbourhoods may increase transport-related and leisure-time physical activity and thus decrease the risk for obesity and obesity-related diseases, such as type 2 diabetes (T2D).We investigated the association between walkability and prevalent/incident T2D in a pooled sample from five German cohorts. Three walkability measures were assigned to participant's addresses: number of transit stations, points of interest, and impedance (restrictions to walking due to absence of intersections and physical barriers) within 640 m. We estimated associations between walkability and prevalent/incident T2D with modified Poisson regressions and adjusted for education, sex, age at baseline, and cohort.Of the baseline 16,008 participants, 1256 participants had prevalent T2D. Participants free from T2D at baseline were followed over a mean of 9.2 years (SD: 3.5, minimum: 1.6, maximum: 14.8 years). Of these, 1032 participants developed T2D. The three walkability measures were not associated with T2D. The estimates pointed toward a zero effect or were within 7% relative risk increase per 1 standard deviation with 95% confidence intervals including 1.In the studied German settings, walkability differences might not explain differences in T2D.
000153121 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000153121 588__ $$aDataset connected to CrossRef, PubMed,
000153121 7001_ $$aSutcliffe, Robynne$$b1
000153121 7001_ $$aSheldon, Mark Patrick$$b2
000153121 7001_ $$aMoebus, Susanne$$b3
000153121 7001_ $$0P:(DE-He78)e0ac0d57cdb66d87f2d95ae5f6178c1b$$aGreiser, Karin Halina$$b4$$udkfz
000153121 7001_ $$aHartwig, Saskia$$b5
000153121 7001_ $$aThürkow, Detlef$$b6
000153121 7001_ $$aStentzel, Ulrike$$b7
000153121 7001_ $$avan den Berg, Neeltje$$b8
000153121 7001_ $$aWolf, Kathrin$$b9
000153121 7001_ $$aMaier, Werner$$b10
000153121 7001_ $$aPeters, Annette$$b11
000153121 7001_ $$aAhmed, Salman$$b12
000153121 7001_ $$aKöhnke, Corinna$$b13
000153121 7001_ $$aMikolajczyk, Rafael$$b14
000153121 7001_ $$aWienke, Andreas$$b15
000153121 7001_ $$00000-0003-4446-9938$$aKluttig, Alexander$$b16
000153121 7001_ $$aRudge, Gavin$$b17
000153121 773__ $$0PERI:(DE-600)2091323-0$$a10.1186/s12902-019-0485-x$$gVol. 20, no. 1, p. 7$$n1$$p7$$tBMC endocrine disorders$$v20$$x1472-6823$$y2020
000153121 909CO $$ooai:inrepo02.dkfz.de:153121$$pVDB
000153121 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e0ac0d57cdb66d87f2d95ae5f6178c1b$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000153121 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000153121 9141_ $$y2020
000153121 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC ENDOCR DISORD : 2017
000153121 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153121 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153121 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153121 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000153121 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000153121 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000153121 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review
000153121 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000153121 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000153121 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000153121 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153121 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153121 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153121 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000153121 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000153121 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000153121 980__ $$ajournal
000153121 980__ $$aVDB
000153121 980__ $$aI:(DE-He78)C020-20160331
000153121 980__ $$aUNRESTRICTED